{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:34:49Z","timestamp":1790796889102,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:00:00Z","timestamp":1476230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T00:00:00Z","timestamp":1476230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11926-016-0617-5","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T03:49:48Z","timestamp":1476244188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Low-Dose IL-2 in the Treatment of Lupus"],"prefix":"10.1007","volume":"18","author":[{"given":"Masayuki","family":"Mizui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,12]]},"reference":[{"issue":"22","key":"617_CR1","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"617_CR2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180\u201390.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"617_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.immuni.2008.11.014","volume":"30","author":"A Yu","year":"2009","unstructured":"Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity. 2009;30(2):204\u201317.","journal-title":"Immunity"},{"issue":"5","key":"617_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283\u201394.","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"617_CR5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea 3rd EP, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055\u201366.","journal-title":"N Engl J Med"},{"issue":"1","key":"617_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","volume":"128","author":"J Koreth","year":"2016","unstructured":"Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft- versus-host disease. Blood. 2016;128(1):130\u20137.","journal-title":"Blood"},{"issue":"22","key":"617_CR7","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067\u201377.","journal-title":"N Engl J Med"},{"issue":"4","key":"617_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295\u2013305.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"617_CR9","unstructured":"\u2022\u2022 He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991\u20133. The newest clinical trial of low-dose IL-2 treatment for 38 SLE patients."},{"key":"617_CR10","doi-asserted-by":"publisher","first-page":"740619","DOI":"10.1155\/2010\/740619","volume":"2010","author":"LA Lieberman","year":"2010","unstructured":"\u2022 Lieberman LA, Tsokos GC. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J Biomed Biotechnol. 2010;2010:740619. This paper summarizes mechanisms of IL-2 deficiency in SLE and its pathogenic roles for the disease progression.","journal-title":"J Biomed Biotechnol"},{"issue":"6","key":"617_CR11","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1172\/JCI78087","volume":"125","author":"VR Moulton","year":"2015","unstructured":"Moulton VR, Tsokos GC. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest. 2015;125(6):2220\u20137.","journal-title":"J Clin Invest"},{"issue":"4-5","key":"617_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/0961203314556139","volume":"24","author":"D Comte","year":"2015","unstructured":"\u2022 Comte D, Karampetsou MP, Tsokos GC. T cells as a therapeutic target in SLE. Lupus. 2015;24(4-5):351\u201363. This paper describes T cell abnormalities, cytokine aberrations in SLE patients and related theraputic options.","journal-title":"Lupus"},{"key":"617_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","volume":"26","author":"TR Malek","year":"2008","unstructured":"Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453\u201379.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"617_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1615\/CritRevImmunol.2014009988","volume":"34","author":"R Arakaki","year":"2014","unstructured":"Arakaki R, Yamada A, Kudo Y, Hayashi Y, Ishimaru N. Mechanism of activation-induced cell death of T cells and regulation of FasL expression. Crit Rev Immunol. 2014;34(4):301\u201314.","journal-title":"Crit Rev Immunol"},{"issue":"9","key":"617_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1084\/jem.20080526","volume":"205","author":"GA Martins","year":"2008","unstructured":"Martins GA, Cimmino L, Liao J, Magnusdottir E, Calame K. Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J Exp Med. 2008;205(9):1959\u201365.","journal-title":"J Exp Med"},{"issue":"3","key":"617_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","volume":"26","author":"A Laurence","year":"2007","unstructured":"Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371\u201381.","journal-title":"Immunity"},{"issue":"5","key":"617_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.immuni.2012.02.012","volume":"36","author":"A Ballesteros-Tato","year":"2012","unstructured":"Ballesteros-Tato A, Leon B, Graf BA, Moquin A, Adams PS, Lund FE, et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity. 2012;36(5):847\u201356.","journal-title":"Immunity"},{"issue":"8","key":"617_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nm.2425","volume":"17","author":"MA Linterman","year":"2011","unstructured":"Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF, et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med. 2011;17(8):975\u201382.","journal-title":"Nat Med"},{"issue":"8","key":"617_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nm.2426","volume":"17","author":"Y Chung","year":"2011","unstructured":"Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med. 2011;17(8):983\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"617_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4049\/jimmunol.1200301","volume":"189","author":"S Le Gallou","year":"2012","unstructured":"Le Gallou S, Caron G, Delaloy C, Rossille D, Tarte K, Fest T. IL-2 requirement for human plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK signaling. J Immunol. 2012;189(1):161\u201373.","journal-title":"J Immunol"},{"issue":"6","key":"617_CR21","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jaci.2015.03.043","volume":"136","author":"B Roediger","year":"2015","unstructured":"Roediger B, Kyle R, Tay SS, Mitchell AJ, Bolton HA, Guy TV, et al. IL-2 is a critical regulator of group 2 innate lymphoid cell function during pulmonary inflammation. J Allergy Clin Immunol. 2015;136(6):1653. 63 e1-7.","journal-title":"J Allergy Clin Immunol"},{"issue":"7293","key":"617_CR22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nature08900","volume":"464","author":"DR Neill","year":"2010","unstructured":"Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367\u201370.","journal-title":"Nature"},{"issue":"4","key":"617_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/eji.200323727","volume":"33","author":"HU Simon","year":"2003","unstructured":"Simon HU, Plotz S, Simon D, Seitzer U, Braathen LR, Menz G, et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells\u2019 syndrome. Eur J Immunol. 2003;33(4):834\u20139.","journal-title":"Eur J Immunol"},{"issue":"4","key":"617_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.yexcr.2012.11.012","volume":"319","author":"R Kang","year":"2013","unstructured":"Kang R, Tang D, Lotze MT, Zeh Iii HJ. Autophagy is required for IL-2- mediated fibroblast growth. Exp Cell Res. 2013;319(4):556\u201365.","journal-title":"Exp Cell Res"},{"issue":"26","key":"617_CR25","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1002569107","volume":"107","author":"C Krieg","year":"2010","unstructured":"Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010;107(26):11906\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"617_CR26","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.2337\/db14-1322","volume":"64","author":"A Yu","year":"2015","unstructured":"Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64(6):2172\u201383.","journal-title":"Diabetes"},{"issue":"6","key":"617_CR27","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/db15-0188","volume":"64","author":"Q Tang","year":"2015","unstructured":"Tang Q. Therapeutic window of interleukin-2 for autoimmune diseases. Diabetes. 2015;64(6):1912\u20133.","journal-title":"Diabetes"},{"issue":"6","key":"617_CR28","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1074\/jbc.M109.053843","volume":"285","author":"JA Ross","year":"2010","unstructured":"Ross JA, Cheng H, Nagy ZS, Frost JA, Kirken RA. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3\/STAT5 activation. J Biol Chem. 2010;285(6):3582\u201391.","journal-title":"J Biol Chem"},{"issue":"5","key":"617_CR29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/ni.3390","volume":"17","author":"SA Apostolidis","year":"2016","unstructured":"Apostolidis SA, Rodriguez-Rodriguez N, Suarez-Fueyo A, Dioufa N, Ozcan E, Crispin JC, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17(5):556\u201364.","journal-title":"Nat Immunol"},{"issue":"4","key":"617_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/jcb.20829","volume":"98","author":"K Tar","year":"2006","unstructured":"Tar K, Csortos C, Czikora I, Olah G, Ma SF, Wadgaonkar R, et al. Role of protein phosphatase 2A in the regulation of endothelial cell cytoskeleton structure. J Cell Biochem. 2006;98(4):931\u201353.","journal-title":"J Cell Biochem"},{"key":"617_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mvr.2013.05.003","volume":"89","author":"A Kasa","year":"2013","unstructured":"Kasa A, Czikora I, Verin AD, Gergely P, Csortos C. Protein phosphatase 2A activity is required for functional adherent junctions in endothelial cells. Microvasc Res. 2013;89:86\u201394.","journal-title":"Microvasc Res"},{"issue":"7","key":"617_CR32","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/art.30353","volume":"63","author":"VC Kyttaris","year":"2011","unstructured":"Kyttaris VC, Zhang Z, Kampagianni O, Tsokos GC. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011;63(7):2058\u201366.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"617_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1172\/JCI22854","volume":"115","author":"YT Juang","year":"2005","unstructured":"Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest. 2005;115(4):996\u20131005.","journal-title":"J Clin Invest"},{"key":"617_CR34","doi-asserted-by":"publisher","unstructured":"Yoshida N, Comte D, Mizui M, Otomo K, Rosetti F, Mayadas T, et al. ICER is requisite for Th17 differentiation. Nat Commun. 2016;7:12993. doi:10.1038\/ncomms12993.","DOI":"10.1038\/ncomms12993"},{"issue":"5","key":"617_CR35","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1172\/JCI73411","volume":"124","author":"T Koga","year":"2014","unstructured":"Koga T, Hedrich CM, Mizui M, Yoshida N, Otomo K, Lieberman LA, et al. CaMK4-dependent activation of AKT\/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance. J Clin Invest. 2014;124(5):2234\u201345.","journal-title":"J Clin Invest"},{"issue":"5","key":"617_CR36","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1073\/pnas.1214207110","volume":"110","author":"VR Moulton","year":"2013","unstructured":"Moulton VR, Grammatikos AP, Fitzgerald LM, Tsokos GC. Splicing factor SF2\/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proc Natl Acad Sci U S A. 2013;110(5):1845\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"617_CR37","doi-asserted-by":"publisher","first-page":"943254","DOI":"10.1155\/2010\/943254","volume":"2010","author":"JC Crispin","year":"2010","unstructured":"Crispin JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:943254.","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"617_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.autrev.2009.02.035","volume":"9","author":"D Gomez-Martin","year":"2009","unstructured":"Gomez-Martin D, Diaz-Zamudio M, Crispin JC, Alcocer-Varela J. Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities. Autoimmun Rev. 2009;9(1):34\u20139.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"617_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/eji.201344280","volume":"45","author":"K Ohl","year":"2015","unstructured":"Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344\u201355.","journal-title":"Eur J Immunol"},{"issue":"7","key":"617_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"\u2022\u2022 von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407\u201315. The first phase I\/IIa clinical trial of low-dose IL-2 for SLE patients.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"617_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.autrev.2008.07.045","volume":"8","author":"I Puliaeva","year":"2009","unstructured":"Puliaeva I, Puliaev R, Via CS. Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE. Autoimmun Rev. 2009;8(3):219\u201323.","journal-title":"Autoimmun Rev"},{"issue":"6281","key":"617_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/346271a0","volume":"346","author":"JC Gutierrez-Ramos","year":"1990","unstructured":"Gutierrez-Ramos JC, Andreu JL, Revilla Y, Vinuela E, Martinez C. Recovery from autoimmunity of MRL\/lpr mice after infection with an interleukin- 2\/vaccinia recombinant virus. Nature. 1990;346(6281):271\u20134.","journal-title":"Nature"},{"issue":"1","key":"617_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/08916939108997143","volume":"10","author":"JC Gutierrez-Ramos","year":"1991","unstructured":"Gutierrez-Ramos JC, Andreu JL, Marcos MA, Vegazo IR, Martinez C. Treatment with IL2\/vaccinia recombinant virus leads to serologic, histologic and phenotypic normalization of autoimmune MRL\/lpr-lpr mice. Autoimmunity. 1991;10(1):15\u201325.","journal-title":"Autoimmunity"},{"issue":"1","key":"617_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1191\/096120399678847308","volume":"8","author":"ML Huggins","year":"1999","unstructured":"Huggins ML, Huang FP, Xu D, Lindop G, Stott DI. Modulation of autoimmune disease in the MRL-lpr\/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus. 1999;8(1):29\u201338.","journal-title":"Lupus"},{"issue":"5","key":"617_CR45","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.4049\/jimmunol.1400977","volume":"193","author":"M Mizui","year":"2014","unstructured":"Mizui M, Koga T, Lieberman LA, Beltran J, Yoshida N, Johnson MC, et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunol. 2014;193(5):2168\u201377.","journal-title":"J Immunol"},{"issue":"12","key":"617_CR46","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","volume":"181","author":"JC Crispin","year":"2008","unstructured":"Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008;181(12):8761\u20136.","journal-title":"J Immunol"},{"issue":"179","key":"617_CR47","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1073\/pnas.0903158107","volume":"5","author":"JY Humrich","year":"2010","unstructured":"Humrich JY, Morbach H, Undeutsch R, Enghard P, Rosenberger S, Weigert O, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A. 2010;5(179):204\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"179","key":"617_CR48","doi-asserted-by":"publisher","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra43.","journal-title":"Sci Transl Med"},{"issue":"10","key":"617_CR49","doi-asserted-by":"publisher","first-page":"18574","DOI":"10.3390\/ijms151018574","volume":"15","author":"A Kosmaczewska","year":"2014","unstructured":"Kosmaczewska A. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity. Int J Mol Sci. 2014;15(10):18574\u201392.","journal-title":"Int J Mol Sci"},{"key":"617_CR50","doi-asserted-by":"publisher","unstructured":"Humrich JY, and Riemekasten G. Restoring regulation - IL-2 therapy in systemic lupus erythematosus. Expert Rev Clin Immunol. 2016:1\u20138. doi:10.1080\/1744666X.2016.1199957.","DOI":"10.1080\/1744666X.2016.1199957"},{"issue":"4","key":"617_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","volume":"74","author":"JY Humrich","year":"2015","unstructured":"\u2022\u2022 Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015;74(4):791\u20132. The first case report of low-dose IL-2 treatment for SLE.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"617_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.17925\/OHR.2014.10.2.157","volume":"10","author":"J Koreth","year":"2014","unstructured":"Koreth J, Ritz J, Tsokos G, Pugliese A, Malek T, Rosenzwajg M, et al. Low-dose interleukin-2 in the treatment of autoimmune disease. Hematol Oncol Rev. 2014;10(2):157\u201363.","journal-title":"Hematol Oncol Rev"},{"issue":"3","key":"617_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/cbr.1993.8.199","volume":"8","author":"T Menzel","year":"1993","unstructured":"Menzel T, Schomburg A, Korfer A, Hadam M, Meffert M, Dallmann I, et al. Clinical and preclinical evaluation of recombinant PEG-IL-2 in human. Cancer Biother. 1993;8(3):199\u2013212.","journal-title":"Cancer Biother"},{"key":"617_CR54","doi-asserted-by":"publisher","first-page":"31562","DOI":"10.1038\/srep31562","volume":"6","author":"K Wu","year":"2016","unstructured":"Wu K, Ma J, Bai W, Cui X, Han T, Wang S, et al. Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model. Sci Rep. 2016;6:31562.","journal-title":"Sci Rep"},{"issue":"12","key":"617_CR55","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763\u201377.","journal-title":"Trends Immunol"},{"issue":"10","key":"617_CR56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nmat3355","volume":"11","author":"J Park","year":"2012","unstructured":"Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, et al. Combination delivery of TGF- beta inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater. 2012;11(10):895\u2013905.","journal-title":"Nat Mater"},{"issue":"12","key":"617_CR57","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.4049\/jimmunol.1501603","volume":"195","author":"K Otomo","year":"2015","unstructured":"Otomo K, Koga T, Mizui M, Yoshida N, Kriegel C, Bickerton S, et al. Cutting edge: nanogel-based delivery of an inhibitor of CaMK4 to CD4+ T cells suppresses experimental autoimmune encephalomyelitis and lupus-like disease in mice. J Immunol. 2015;195(12):5533\u20137.","journal-title":"J Immunol"},{"key":"617_CR58","doi-asserted-by":"crossref","unstructured":"Comte D, Karampetsou MP, Kis-Toth K, Yoshida N, Bradley SJ, Mizui M, et al. Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proc Natl Acad Sci USA. 2016;113(33):9321\u20136.","DOI":"10.1073\/pnas.1605081113"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-016-0617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-016-0617-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-016-0617-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:46:26Z","timestamp":1684863986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-016-0617-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,12]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1007\/s11926-016-0617-5","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,12]]},"assertion":[{"value":"12 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Drs. Mizui and Tsokos declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"68"}}